Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.52 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31479382 | 1.00 | KCNH2 (0.52) | KCNH2SCN3AALDH1A1OPRK1LMNA | |
| SCHEMBL2051542 | 0.86 | KCNH2 (0.44) | KCNH2SCN3A | |
| SCHEMBL20533458 | 0.86 | KCNH2 (0.44) | KCNH2SCN3A | |
| SCHEMBL2051541 | 0.86 | KCNH2 (0.44) | KCNH2SCN3A | |
| SCHEMBL24220439 | 0.86 | KCNH2 (0.49) | KCNH2SCN3AALDH1A1LMNA | |
| SCHEMBL20835748 | 0.86 | KCNH2 (0.49) | KCNH2SCN3AALDH1A1LMNA | |
| SCHEMBL8695116 | 0.85 | KCNH2 (0.48) | KCNH2SCN3AOPRK1 | |
| SCHEMBL8695113 | 0.85 | KCNH2 (0.48) | KCNH2SCN3AOPRK1 | |
| SCHEMBL2036845 | 0.84 | SLC6A3 (0.51) | KCNH2SCN3A | |
| SCHEMBL2036846 | 0.84 | SLC6A3 (0.51) | KCNH2SCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256186-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1663975-A1 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| WO-2005028440-A1 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | KCNH2 2312/4885SCN3A 190/4885ALDH1A1 4012/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | KCNH2 3247/4885SCN3A 127/4885ALDH1A1 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.